These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

494 related articles for article (PubMed ID: 23294160)

  • 21. Implications of the Cardiac Arrhythmia Suppression Trial for antiarrhythmic drug treatment.
    Bigger JT
    Am J Cardiol; 1990 Feb; 65(8):3D-10D; discussion 68D-71D. PubMed ID: 2106253
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical use of class IC antiarrhythmic drugs.
    Abi Samra F
    J La State Med Soc; 1989 May; 141(5):27-31. PubMed ID: 2499646
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide.
    Taylor R; Gandhi MM; Lloyd G
    BMJ; 2010 Mar; 340():b4684. PubMed ID: 20219811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A symposium: Supraventricular Arrhythmias: Update 1995. Boston, Massachusetts, May 6, 1995.
    Am J Cardiol; 1996 Jan; 77(3):1A-95A. PubMed ID: 8607386
    [No Abstract]   [Full Text] [Related]  

  • 25. [Intravenous flecainide administration for conversion of paroxysmal atrial fibrillation in the emergency room].
    Antonelli D; Feldman A; Freedberg NA; Darawsha A; Rosenfeld T
    Harefuah; 2006 May; 145(5):342-4, 398. PubMed ID: 16805213
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Flecainide: Electrophysiological properties, clinical indications, and practical aspects.
    Paolini E; Stronati G; Guerra F; Capucci A
    Pharmacol Res; 2019 Oct; 148():104443. PubMed ID: 31493514
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The role of an electropharmacological transesophageal test in the prevention of paroxysmal atrial fibrillation. Experience with flecainide].
    De Sisti A; Matteucci C; Patrissi T; Accogli S; Di Lorenzo M; Sasdelli M; Ciolli A; Lo Sardo G; Palamara A
    G Ital Cardiol; 1998 Dec; 28(12):1391-9. PubMed ID: 9887393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Flecainide: its value and danger.
    Malik R; Ellenbogen KA; Stambler BS; Wood MA
    Heart Dis Stroke; 1994; 3(2):85-9. PubMed ID: 8199770
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of flecainide on atrial and ventricular refractoriness and conduction in patients with normal left ventricle. Implications for possible antiarrhythmic and proarrhythmic mechanisms.
    Katritsis D; Rowland E; O'Nunain S; Shakespeare CF; Poloniecki J; Camm AJ
    Eur Heart J; 1995 Dec; 16(12):1930-5. PubMed ID: 8682029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation.
    Aliot E; Capucci A; Crijns HJ; Goette A; Tamargo J
    Europace; 2011 Feb; 13(2):161-73. PubMed ID: 21138930
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Encainide and flecainide: are they interchangeable?
    Saini V; Podrid PJ; Slater W; Lown B
    Am Heart J; 1989 Jun; 117(6):1253-8. PubMed ID: 2499169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [What is the latest in anti-arrhythmia therapy?].
    Gloor HO
    Schweiz Med Wochenschr; 1991 Nov; 121(47):1711-4. PubMed ID: 1720259
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiarrhythmic properties of ranolazine--from bench to bedside.
    Tzeis S; Andrikopoulos G
    Expert Opin Investig Drugs; 2012 Nov; 21(11):1733-41. PubMed ID: 22916846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of oral flecainide acetate in patients with cardiac arrhythmias.
    Nakazato Y; Nakata Y; Yasuda M; Nakazato K; Sumiyoshi M; Ogura S; Yamaguchi H
    Jpn Heart J; 1997 May; 38(3):379-85. PubMed ID: 9290572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Encainide hydrochloride and flecainide acetate: two class 1c antiarrhythmic agents.
    Chase SL; Sloskey GE
    Clin Pharm; 1987 Nov; 6(11):839-50. PubMed ID: 3119276
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Flecainide for the Treatment of Atrial Fibrillation.
    Echt DS; Ruskin JN
    Am J Cardiol; 2020 Apr; 125(7):1123-1133. PubMed ID: 32044037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Comparative study of cibenzoline and flecainide by oral route for preventing recurrence of paroxysmal atrial tachyarrhythmias].
    Maison-Blanche P; Brembilla-Perrot B; Fauchier JP; Babuty D; Garnier LF; Rouesnel P; Breuillac JC; Funck F; Scheck F; Peraudeau P; Medvedowsky JL
    Ann Cardiol Angeiol (Paris); 1997 Feb; 46(2):109-16. PubMed ID: 9137677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of resistant atrial fibrillation. A meta-analysis comparing amiodarone and flecainide.
    Zarembski DG; Nolan PE; Slack MK; Caruso AC
    Arch Intern Med; 1995 Sep; 155(17):1885-91. PubMed ID: 7677555
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Flecainide therapy in patients treated for supraventricular tachycardia with near normal left ventricular function.
    Hughes MM; Trohman RG; Simmons TW; Castle LW; Wilkoff BL; Morant VA; Maloney JD
    Am Heart J; 1992 Feb; 123(2):408-12. PubMed ID: 1736577
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Epidemiology and therapy of atrial fibrillation].
    Capucci A; Aschieri D; Villani GQ
    Ann Ital Med Int; 1996 Oct; 11 Suppl 2():5S-10S. PubMed ID: 9004821
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.